The July 2026 structural buckling at the former Pfizer headquarters during its major office-to-residential conversion in Midtown Manhattan—tied to missing steel reinforcements on load-bearing columns—prompted a preliminary criminal inquiry alongside the Department of Buildings probe. Yet months later, with stabilization complete and repair plans approved for gradual floor jacking, no charges have materialized against developers, contractors, or engineers despite prior safety violations at the site. The focus remains on civil litigation, project recovery, and broader construction oversight sweeps that found no systemic risks in similar conversions. Traders appear to weigh the slow pace of complex liability determinations and typical timelines for such cases, viewing criminal outcomes by year-end as the less probable path.